[PDF] Top 20 Development of Aseptic Renal Abscess in a Patient with Non Small Cell Lung Cancer with ALK Translocation during Crizotinib Treatment
Has 10000 "Development of Aseptic Renal Abscess in a Patient with Non Small Cell Lung Cancer with ALK Translocation during Crizotinib Treatment" found on our website. Below are the top 20 most common "Development of Aseptic Renal Abscess in a Patient with Non Small Cell Lung Cancer with ALK Translocation during Crizotinib Treatment".
Development of Aseptic Renal Abscess in a Patient with Non Small Cell Lung Cancer with ALK Translocation during Crizotinib Treatment
... the patient presented increase of the abscess content after the reintroduction of Crizotinib, so we opt for the suspension of Crizotinib with significant decrease of the ...of renal ... See full document
5
Case Report HIP1-ALK fusion variant in non-small-cell lung cancer and response to crizotinib: a case report and review of the literature
... this patient was considered as partial response (PR) to ...crizotinib. During treatment of crizotinib, abnor- mal hepatic and renal function after adminis- tration were not ... See full document
5
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
... the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung ... See full document
16
<p>Brigatinib for <em>ALK</em>-positive metastatic non-small-cell lung cancer: design, development and place in therapy</p>
... in ALK, compared to crizo- tinib, ceritinib and ...four ALK TKIs were analyzed in an in vitro mutagenesis screen using Ba/F3 cells expressing native ...any ALK secondary mutant at 500 nmol/L, whereas ... See full document
12
<p>Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives</p>
... increases during the course of the disease to as high as 60% for crizotinib-resistant ALK+ ...IV ALK+ NSCLC patients have pro- longed ...IV ALK+ NSCLC patients. 19 This is due to the ... See full document
9
Crizotinib in non small cell lung cancer
... (53%), non-smokers (65%), diagnosed with ade- nocarcinoma (92%), having an ECOG performance sta- tus of 0 - 2 (83%) and received ≥2 lines of chemotherapy ...of treatment was 25 weeks (treatment ... See full document
5
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
... a treatment option in metastatic non-small cell lung cancer, for which oncogenic drivers have been ...and non-squamous lung cancer. The EML4–ALK gene ... See full document
9
Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
... like ALK or ROS1; and cohort 5 – crizotinib-naïve or crizotinib-treated, ALK-rearranged NSCLC with active and measurable intracranial ...adequate renal, hepatic, and bone marrow ... See full document
9
Clinical use of crizotinib for the treatment of non-small cell lung cancer
... of non-small cell lung cancer (NSCLC) and small cell lung ...clinical development of crizotinib for these patients is the most recent clinical example ... See full document
11
Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
... Abstract: Lung cancer has become one of the leading causes of death in both men and women in the United States, with approximately 230,000 new cases and 160,000 deaths each ...of lung cancer ... See full document
8
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
... advanced non-small-cell lung cancers (NSCLCs) have an ALK rear- rangement at the time of ...subtype. Crizotinib is a tyrosine kinase inhibitor, targeting ALK, ROS1, RON, ... See full document
8
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
... in ALK positive population, most patients progress under ALK inhibitors within first 2 years; being the brain the most frequent site of ...relapse. ALK mutations, in ~30% of patients, are the main ... See full document
8
<p>The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis</p>
... of non-small cell lung cancer (NSCLC) patients have anaplastic lymphoma kinase (ALK) ...of ALK inhibitors have been used for ALK-positive NSCLC treatment, ... See full document
10
Surgical treatment in non small cell lung cancer with pulmonary oligometastasis
... new treatment strategies based on new diagnostic criteria and aggressive treatment options must be ...multiple lung cancers, both ipsilaterally (n = 27) and contralaterally (n = 28), the 5-year ... See full document
5
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer
... the patient-re- ported benefit of alectinib’s CNS activity, including the relationship between best overall response (complete or partial) and emotional functioning and cognitive func- ... See full document
8
<p>Responses to <em>ALK</em> Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel <em>HPCAL1-ALK</em> Fusion Variant: A Case Report</p>
... on crizotinib treatment was superior to that of patients with EML4 (exon 6)- ALK (exon 20) variants, 16 suggesting that it is of great signi fi cance to evaluate the ef fi cacy of crizotinib ... See full document
5
Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report
... Although crizotinib-induced ILD in ROS1-positive NSCLC patients has not been systematically character- ized before, patients with ROS1 rearrangements had a similar incidence ...ing ALK rearrangements ...of ... See full document
6
First-line treatment of advanced ALK-positive non-small-cell lung cancer
... of crizotinib. Given the important activity of crizotinib in two patients with NSCLC with ALK rearrangement, this Phase I study was extended in this particular molecular ...of ALK ... See full document
12
<p>Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer</p>
... circulating cell-free DNA were extracted from fresh or formalin- fi xed, paraf fi n-embedded (FFPE) tumor samples and blood samples, respectively, according to optimized ...168 cancer- related genes (Burning ... See full document
9
lincROR influences the stemness and crizotinib resistance in EML–ALK<sup>+</sup> non-small-cell lung cancer cells
... Clinical tissues were collected from 106 patients who underwent a surgical procedure at the Zhongnan Hospital of Wuhan University (Wuhan, Hubei, China) between 2011 and 2016. No patient received therapy before ... See full document
9
Related subjects